Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06381024Not ApplicableCompleted

A Study of Telemonitoring in Cancer Patients

Role: collaborator

NCT06371911Not ApplicableCompleted

Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment

Role: collaborator

NCT06505018Not ApplicableRecruiting

Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

Role: collaborator

NCT05653609Completed

Sensitivity and Specificity of the Clinical Classifications Generated by the Cureety Digital Telemonitoring Tool

Role: lead

All 4 trials loaded